Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 4/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7063524 | 0.88 | LIPG (0.31) | — | |
| SCHEMBL7061509 | 0.86 | HPGD (0.43) | ALDH1A1KMT2A | |
| SCHEMBL6695961 | 0.85 | MMP1 (0.36) | ALDH1A1KMT2A | |
| SCHEMBL7120254 | 0.85 | PDPK1 (0.40) | ALDH1A1L3MBTL1MDM2S1PR3KMT2A | |
| SCHEMBL6683778 | 0.79 | PARP1 (0.39) | SIGMAR1ALDH1A1TSHRL3MBTL1TLR7 | |
| SCHEMBL6678246 | 0.79 | ALDH1A1 (0.36) | SIGMAR1ALDH1A1TSHRL3MBTL1TLR7 | |
| SCHEMBL6678771 | 0.79 | ALDH1A1 (0.39) | SIGMAR1ALDH1A1TSHRL3MBTL1TLR7 | |
| SCHEMBL6692406 | 0.78 | ALDH1A1 (0.36) | SIGMAR1ALDH1A1TSHRL3MBTL1PTGS1 | |
| SCHEMBL7061233 | 0.77 | ABCB1 (0.35) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL7131191 | 0.75 | MMP1 (0.40) | ALDH1A1L3MBTL1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | SIGMAR1 4681/4885ALDH1A1 812/4885TSHR 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.